Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2/3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Gynecologic 1

Conditions

Polycystic Ovary Syndrome 2Weight Gain 1Peripheral Nervous System Diseases 1Overweight 1Obesity 1Myasthenia Gravis 1Infertility 1Endometrial Neoplasms 1

Interventions

Megestrol Acetate 4Letrozole 4Paclitaxel 3Medroxyprogesterone Acetate 3Carboplatin 3Gonadotropin-Releasing Hormone 2Cisplatin 2spartalizumab 1sintilimab 1ricin A-GnRH conjugate 1olaparib 1niraparib 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1durvalumab 1atezolizumab 1Tablets 1Progestins 1Progesterone 1Observation 1LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)- 1Drug Therapy 1Cyproterone acetate, ethinyl estradiol drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Endometrial Neoplasms × Tablets × Clear all
NCT05316467 2025-08-11

Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma

Fudan University

Phase 2/3 Recruiting
89 enrolled
GynecologicOther

Infertility, Obesity, Endometrial Neoplasms, Overweight

Data powered by HemOnc (CC BY 4.0) Colophon âš¡